Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14248374 | 1.00 | RAB9A (0.39) | RAB9AHSD17B10NPSR1TP53SLC7A5 | |
| SCHEMBL14247750 | 1.00 | RAB9A (0.39) | RAB9AHSD17B10NPSR1TP53SLC7A5 | |
| SCHEMBL735831 | 0.77 | HSD17B10 (0.42) | RAB9AHSD17B10NPSR1TP53MAPT | |
| SCHEMBL18258606 | 0.77 | HSD17B10 (0.42) | RAB9AHSD17B10NPSR1TP53MAPT | |
| SCHEMBL9735203 | 0.73 | RAB9A (0.37) | RAB9ATP53SLC7A5MEN1KMT2A | |
| SCHEMBL9442658 | 0.71 | MAPT (0.34) | RAB9ATP53MAPTMEN1KMT2A | |
| SCHEMBL4600810 | 0.70 | HSD17B10 (0.37) | RAB9AHSD17B10NPSR1MAPTPOLB | |
| SCHEMBL27551712 | 0.69 | MAPT (0.35) | RAB9AHSD17B10NPSR1TP53MAPT | |
| SCHEMBL498341 | 0.69 | HSD17B10 (0.43) | HSD17B10NPSR1POLBSMN1; SMN2TDP1 | |
| SCHEMBL7936004 | 0.67 | HSD17B10 (0.42) | HSD17B10NPSR1TP53POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796640-B2 | Method for producing optically active carboxylic acid ester | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20170008820-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2017-01-12 | — | — | US | disclosed |
| EP-3098217-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | Tokyo University of Science Foundation (JP) | 2016-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008820-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER | ADH1A, ALDH1A2, ADH1C | RAB9A 456/4885HSD17B10 194/4885NPSR1 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.